Brought to you by 
Gamida Cell closes $40mm Series F round
20 Jun 2017
Executive Summary
Gamida Cell Ltd. (cell and immunotherapies for cancer) raised $40mm through what appears to be its Series F round. (The funding is the first for the company since closing a $10mm Series E in 2012.) New investor Shavit Capital led and was joined by other first-time buyers VMS Investment Group and Israel Biotech fund, along with returning backers Novartis, Clal Biotechnology, and Israel HealthCare Ventures. Proceeds will support completion of Phase III trials and future commercialization of NiCord, an ex vivo expanded cell graft from umbilical cord stem cells indicated for bone marrow transplantation in blood cancer patients who do not have a fully matched donor.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gamida Cell closes $40mm Series F round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice